£1.1bn biotech deal just the tonic for Simmons
Simmons & Simmons has advised Danish biotech company Genmab on its £1.1bn licensing deal with drugs giant GlaxoSmithKline (GSK) in one of the largest…
January 17, 2007 at 07:13 PM
2 minute read
Simmons & Simmons has advised Danish biotech company Genmab on its £1.1bn licensing deal with drugs giant GlaxoSmithKline (GSK) in one of the largest ever commercial agreements in the life sciences sector.
Simmons head of intellectual property Richard Binns advised longstanding client Genmab on its deal with GSK to co-develop an antibody product and release it to the market. The product could potentially be used in the treatment of certain cancers and rheumatoid arthritis.
Both Genmab and GSK are Simmons clients, meaning the firm had to get permission from GSK to act for Genmab on this occasion.
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Trending Stories
- 1First Lawsuit Filed Alleging Contraceptive Depo-Provera Caused Brain Tumor
- 2BD Settles Thousands of Bard Hernia Mesh Lawsuits
- 3The Law Firm Disrupted: For Big Law Names, Shorter is Sweeter
- 4The Growing Tension—And Opportunity—in Big Law Nonequity Tiers
- 5The 'Biden Effect' on Senior Attorneys: Should I Stay or Should I Go?
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250